Plus Therapeutics presents REYOBIQ data at neurosurgery meeting

Plus Therapeutics Inc. (NASDAQ: PSTV) presented clinical data for its radiopharmaceutical REYOBIQ at the 2026 American Association of Neurological Surgeons Annual Scientific Meeting in San Antonio, Texas.

The presentation covered results from the Phase 1 ReSPECT-LM trial of REYOBIQ (rhenium Re186 obisbemeda) for treating leptomeningeal metastases. The study showed median overall survival of approximately 9 months in patients treated at the recommended Phase 2 dose, according to the company's statement.

The trial demonstrated what the company described as robust anti-tumor activity, including reductions in circulating tumor cells and clinical benefit across evaluable patients. The treatment showed a target-to-off-target absorbed dose ratio exceeding 100:1, the company reported.

Translational analyses indicated that REYOBIQ may induce immune remodeling within the tumor microenvironment, including activation of CD8+ T cells, according to the presentation data.

"This oral plenary session, which reviewed data collected to date, and included an overview of the ReSPECT-LM single dose escalation study, is an important validation of the clinical and translational evidence supporting REYOBIQ," said Eric J. Daniels, the company's Chief Development Officer.

The ReSPECT-LM Phase 1 Multiple Dose trial is currently enrolling patients at the University of Texas Health San Antonio. REYOBIQ is an injectable radiotherapy designed to deliver targeted radiation for central nervous system tumors.

Plus Therapeutics is developing the treatment for leptomeningeal metastases, a condition with no FDA-approved therapies. The company is also evaluating REYOBIQ for recurrent glioblastoma and pediatric brain cancer in separate clinical trials.

You May Also Be Interested In

• FDA Committee Recommends To Widen Access To Bpc-157 Peptide
• Faraday Future demos FF Master robot at Maker Faire meetups
• Nvidia and KAIST launch $300M joint AI research lab in Seoul